uniQure: Shares Tumble On Fresh FDA Controversy - What Investors Should Know
Source: SeekingAlpha
2026-02-27 10:49:58 ET
Investment Overview
Shares of the Amsterdam, Netherlands based gene therapy specialist drug developer uniQure N.V. ( QURE ) were in freefall yesterday, dropping by >30% as the market digested comments made by FDA commissioner Dr Marty Makary during an interview with CNBC, that many observers believe may have referenced UniQure's therapy AMT-130, indicated to treat Huntington's Disease....
Read the full article on Seeking Alpha
For further details see:
uniQure: Shares Tumble On Fresh FDA Controversy - What Investors Should Know
uniQure N.V.
NASDAQ: QURE
QURE Trading
18.55% G/L:
$20.035 Last:
2,309,692 Volume:
$17.97 Open:
QURE Latest News
April 30, 2026 07:05:00 am
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease
QURE Stock Data
$1,555,111,367
59,307,892
N/A
61
N/A
Biotechnology & Life Sciences
Healthcare
NL
Amsterdam
